PureTech Health (PRTC) announced that the first patient has been dosed in the Phase 2b BUOY-1 study of GlyphAllo SPT-300 or Glyph Allopregnanolone in major depressive disorder with or without anxious distress.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTC:
- PureTech Health CEO Bharatt Chowrira steps down
- PureTech Health says Raju Kucherlapati steps down as board chair
- PureTech Health founded entity Vor Bio enters license agreement with RemeGen
- Positive Outlook on PureTech Health Driven by Promising LYT-100 Clinical Trial Results and Strategic Developments
- PureTech Health presents deupirfenidone data at ATS conference